Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The innovation arm of Oxford University gains impact at board level with the addition of the former Minister for Public Health and Innovation and the former Chief Executive of Oxford Instruments.

Nicola Blackwood, the former Minister for Public Health and Innovation and MP for Oxford West and Abingdon, and Jonathan Flint, the former chief executive of the University’s first spinout company Oxford Instruments, have joined Oxford University Innovation’s (OUI) board as non-executive directors.

Nicola Blackwood was Chair of the Science & Technology Select Committee while in Parliament. There, she led inquiries into the science budget, big data, digital skills, space and satellites, and how UK science would be affected by the EU Referendum. As Minister for Public Health and Innovation, she held a portfolio that covered life sciences, mental health, global health security, and public health. Since leaving office, she has taken up a number of board roles, and acts as an advisor to innovation-focused companies.

Jonathan Flint is the President Elect of the Institute of Physics and the former Chief Executive Officer of Oxford Instruments. He has held managing director positions at BAE Systems, Vislink and EADS. At present, Jonathan holds board positions with Stadium plc, the Oxford Trust, and now OUI.

Find out more (Oxford University Innovation website)

Similar stories

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Oxford to collaborate with Janssen to map the cellular landscape of immune mediated disorders

General Innovation

The University of Oxford announced today that it has entered into a strategic collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

BioEscalator’s Enara Bio partners with Boehringer Ingelheim to develop novel cancer immunotherapies

General Innovation

Enara Bio, a start-up located in the University’s BioEsclator, has announced a strategic collaboration and licensing agreement with Boehringer Ingelheim, worth over €876M (£787M), to lead the discovery and validation of Dark Antigens to target lung and gastrointestinal cancers.

Investigating New Treatment for Schizophrenia

General Innovation Research

A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia.

£100 million donation from Ineos to create new institute to fight antimicrobial resistance

Awards and Appointments General Innovation

A new state of the art institute for antimicrobial research is to open at Oxford University thanks to a £100 million donation from Ineos.

University spinout PepGen awarded major financing to target Duchenne muscular dystrophy

Awards and Appointments General Innovation

PepGen, a therapeutics company targeting severe neuromuscular diseases, including Duchenne muscular dystrophy (DMD), has closed a $45 million Series A funding round led by RA Capital Management with participation from Oxford Sciences Innovation (OSI), the company’s original seed investor.